The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for older adult patients with unresectable pancreatic cancer: A prospective study.
 
Kenji Ikezawa
Speakers' Bureau - Asahi Kasei; Incyte; MSD; Myriad Genetics; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - ASKA Pharmaceutical
 
Toshihiro Imai
No Relationships to Disclose
 
Ryoji Takada
Speakers' Bureau - Hisamitsu Pharmaceutical; Novartis; TEIJIN PHARMA
 
Takuo Yamai
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
 
Nobuyasu Fukutake
No Relationships to Disclose
 
Kazuyoshi Ohkawa
Speakers' Bureau - Chugai Pharma; Eisai; Gilead Sciences; Hisamitsu Pharmaceutical; Incyte; Takeda; Yakult Honsha
Research Funding - Sumitomo Chemical; Towa Pharmaceutical